Autoimmune thyroid disease and segmental myoclonus.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Bryan Young.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
CONTEXT: The focus of thrombolytic therapy in acute stroke has been on favorable outcome at 3 months. Few studies have analyzed outcome at 24 hours. An early and reliable prediction of poor outcome has implications for clinical management and discharge planning. OBJECTIVE: To evaluate predictors of lack of improvement at 24 hours after receiving alteplase and their relationship with poor outcome at 3 months. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort of consecutive patients with acute stroke who received alteplase and were admitted to a university hospital from January 1999 to March 2003. Participants were recruited from 2 academic centers in a major city in Ontario and 33 affiliated hospitals from 7 counties. MAIN OUTCOME MEASURES: Lack of improvement defined as a difference between the National Institutes of Health Stroke Scale score at baseline and at 24 hours of 3 points or less. Poor outcome at 3 months defined by a modified Rankin Scale score of 3 to 5 or death. RESULTS: Among 216 patients with acute stroke who were treated with alteplase, 111 (51.4%) had a lack of improvement at 24 hours. After adjusting for age, sex, and stroke severity, baseline glucose level on admission (odds ratio [OR] 2.89; 95% confidence interval [CI], 1.40-5.99 for a glucose level >144 mg/dL [>8 mmol/L]), cortical involvement (OR, 2.66; 95% CI, 1.36-5.20), and time to treatment (OR, 1.01; 95% CI, 1.0-1.02 for each 1 minute increase in time to treatment) were independent predictors of lack of improvement. At 3 months, 43 patients (20.2%) had died; of the 170 survivors, 75 patients (44%) had poor outcomes. After adjusting for age, sex, and stroke severity, lack of improvement at 24 hours was an independent predictor of poor outcome (OR, 12.9; 95%CI, 5.7-29.6) and death (OR, 7.5; 95% CI, 2.9-19.6). Patients with a lack of improvement had longer lengths of hospitalization (14.5 vs 9.6 days; P = .02). CONCLUSIONS: Among patients with acute stroke treated with thrombolytic therapy, lack of improvement at 24 hours is associated with poor outcome and death at 3 months. Elevated glucose level, time to thrombolytic therapy, and cortical involvement were predictors of lack of improvement.
OBJECTIVE: The description and application of a new, overlap-integral comparison method and the quantification of human vs. human accuracies that can be used as goals for algorithms. METHODS: Four human experts marked ten 8 h electroencephalography (EEG) records from seizure patients. The seizures varied in origin and type, including complex partial, generalized absence, secondarily generalized and primary generalized tonic-clonic. The traditional any-overlap comparison method is used in addition to the overlap-integral method, which is sensitive to the correct placement of the seizure endpoints. RESULTS: The number of events marked by each reader ranged from 57 to 77. The average any-overlap sensitivity and false positives per hour rate are 0.92 and 0.117. The average overlap-integral correlation, sensitivity and specificity are 0.80, 0.82 and 0.9926. As expected, the correspondence between readers is high, but confounding issues resulted in overlap-integral sensitivities less than 0.5 for 10% of the records. Seven percent of the any-overlap sensitivities are less than 0.5. A comparison of the methods by record shows that the overlap-integral specificity and the any-overlap false positive rate measure different features. CONCLUSIONS: There was little variation between readers and they were essentially interchangeable. High seizure rate (many per hour), short seizure durations (<10 s) and long seizure durations (approximately 10 min) with ambiguous offsets can complicate the analysis and result in poor correlation. There may be any number of unmarked events in rigorously marked records and it may be preferable to use records from non-epilepsy patients to compute the false positive rate. The any-overlap and overlap-integral comparison methods are complementary. SIGNIFICANCE: Correlation between expert human readers can be low on some records, which will complicate testing of seizure detection algorithms.
To investigate genetic alterations in primary cutaneous B-cell lymphomas (PCBCLs), we have analyzed 29 cases of PCBCL. Comparative genomic hybridization showed chromosome imbalances (CIs) in 12 cases (41%). The mean number of CIs per sample was 2.05 +/- 2.97, with gains (1.48 +/- 2.38) more frequent than losses (0.56 +/- 1.40). The common regions of gains were 18/18q (50%), 7/7p (42%), 3/3q (33%), 20 (33%), 1p (25%), 12/12q (25%), and 13/13q (25%), whereas loss of 6q was frequent (42%). Among the different subsets of PCBCLs, CI was seen in 50% of diffuse large-cell lymphomas (DLCLs), 33% of marginal zone lymphomas, and 8% of follicle center cell lymphomas and unclassified lymphomas. A similar pattern of CI was observed in these lymphomas, but loss of 6q and gains of 3/3q were present only in DLCLs. Microarray-based genomic analysis of four DLCL cases identified oncogene gains of SAS/CDK4 (12q13.3) in three cases and MYCL1 (1p34.3), MYC (8q24), FGFR2 (10q26), BCL2 (18q21.3), CSE1L (20q13), and PDGFB (22q12-13) in two cases, whereas losses of AKT1 (14q32.3), IGFR1 (15q25-26), and JUNB (19p13.2) were identified in three cases, and losses of FGR (1p36), ESR (6q25.1), ABL1 (9q34.1), TOP2A (17q21-22), ERBB2 (17q21.2), CCNE1 (19q13.1), and BCR (22q11) were each identified in two cases. In addition, real-time-polymerase chain reaction detected amplification of BCL2 in 5 of 29 cases. These findings suggest that there are complex but consistent genetic alterations associated with the pathogenesis of PCBCLs.
The authors describe a novel EEG artifact in two patients whose records were otherwise suppressed. The saw-toothed waveform, containing 5.5- and 11-Hz rhythms, was induced as a movement artifact by a hemoperfusion machine connected to the patient. The artifact is highly characteristic, but could be easily misinterpreted as a cerebral rhythm if one is not aware of the entity. The artifact should be suspected when invariant, saw-toothed rhythms appear beyond the temporal and occipital lobes, and also contaminate the electrocardiographic channel. It can be proved by its disappearance on stopping and reemergence with starting the rotary pump action of the device.
Explore the source record for details and available documents.